Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

CH25H-mediated cholesterol metabolism drives chondrogenic differentiation in adipose-derived stem cells and enhances cartilage repair.

Wang Y., Ye W., Chen Y., Zhuang Y., Qin Z., Luo D.

Animal Study on Cartilage Damage, published in Commun Biol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Commun Biol (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41974925
PMCID
PMC13265959
DOI
10.1038/s42003-026-10041-1

Abstract (original English)

Cartilage defects are difficult to heal because articular cartilage is both avascular and aneural. Directing adipose-derived mesenchymal stem cells (ADSCs) toward a chondrogenic fate in vitro is regarded as a promising therapeutic strategy. However, the endogenous pathways that specify chondrogenic fate remain incompletely defined. Herein, we identify cholesterol-25-hydroxylase (CH25H) as a key inducer of early chondrogenic differentiation that upregulates the cartilage marker genes SOX9, ACAN, and COL2A1. In ADSCs, FPR1 knockdown and rescue experiments, together with pharmacological inhibition of FPR1 or AKT, supported a signalling model in which 25-HC engages FPR1 to promote AKT/GSK3β pathway activation and chondrogenic differentiation. Surface plasmon resonance assays show that 25-HC directly binds to FPR1 with a dissociation constant of 1.18 µM. Molecular docking and membrane MD/MM/GBSA analyses provided structural context, suggesting stable accommodation of 25-HC in an FPR1 pocket and nominating candidate contacts (including a F81/V105 hydrophobic clamp) for future mutagenesis. In a rat trochlear cartilage-defect model, intra-defect implantation of ADSC-laden hydrogel combined with weekly intra-articular 25-HC dosing was associated with improved repair features, while co-administration of Cyclosporin H/HCH6-1 reduced these benefits. Together, these findings delineate the C

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCholesterolChondrogenesisCell DifferentiationRatsMesenchymal Stem CellsAdipose TissueCartilage, ArticularSignal TransductionMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research